

MILLENNIUM CHEMICALS INC  
Form 10-Q/A  
November 14, 2003

=====

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----

FORM 10-Q/A  
(AMENDMENT NO. 1)

-----

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2003

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: 1-12091

-----

MILLENNIUM CHEMICALS INC.  
(Exact name of registrant as specified in its charter)

-----

Delaware  
(State or other jurisdiction of  
incorporation or organization)

22-3436215  
(I.R.S. Employer Identification No.)

20 Wight Avenue, Suite 100  
Hunt Valley, MD 21030  
(Address of principal executive offices)

410-229-4400  
(Registrant's telephone number, including area code)

-----

Indicate by check mark whether the registrant (1) has filed all reports  
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of  
1934 during the preceding 12 months (or for such shorter period that the  
Registrant is required to file such reports) and (2) has been subject to such  
filing requirements for the past 90 days. Yes  No .

Indicate by check mark whether the registrant is an accelerated filer (as  
defined in Rule 12b-2 of the Act). Yes  No .

Indicate the number of shares outstanding of each of the issuer's classes

Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

of common stock, as of the latest practicable date: 63,487,435 shares of Common Stock, par value \$.01 per share, as of April 30, 2003, excluding 14,409,151 shares held by the registrant, its subsidiaries and certain Company trusts, which are not entitled to vote.

=====

MILLENNIUM CHEMICALS INC.

TABLE OF CONTENTS

|   | Page |
|---|------|
|   | ---  |
| Explanatory Note.....   | 2    |
| Part I FINANCIAL INFORMATION  |      |
| Item 1 Financial Statements.....  | 6    |
| Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations..... | 27   |
| Item 4 Controls and Procedures.....   | 36   |
| Part II OTHER INFORMATION   |      |
| Item 6 Exhibits and Reports on Form 8-K.....  | 37   |
| Signature.....  | 38   |
| Certifications.....   | 40   |

Explanatory Note

Millennium Chemicals Inc. (the "Company") is filing this amendment to its Quarterly Report on Form 10-Q for the period ended March 31, 2003 to reflect restatements of its financial statements for the years ended December 31, 1998 through 2002 and for the first quarter of 2003. Included herein are restated consolidated statements of operations and consolidated statements of cash flows for each of the three months ended March 31, 2003 and 2002, and restated consolidated balance sheets as of March 31, 2003 and December 31, 2002. The restatements correct errors in:

- o the accounting for deferred taxes relating to the Company's investment in Equistar Chemicals, LP ("Equistar"), a partnership in which the Company owns a 29.5% interest;
- o the calculation of the Company's minimum pension benefit liability as reflected in its balance sheet at December 31, 2002 and its pension expense for the year then ended, as a result of actuarial valuation

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

errors by the Company's independent actuarial valuation firm; and

- o the accounting for a five-year precious metals agreement entered into in April 1998 that had been characterized as an operating lease and should have been characterized as a secured financing.

These errors, all of which were discovered in July 2003, were initially reported by the Company on August 6, 2003, in a press release, a copy of which was appended as an exhibit to a Current Report on Form 8-K of the same date.

In addition, during the course of its review of its deferred tax assets related to its investment in Equistar, the Company reexamined the deferred tax asset associated with its French subsidiaries and concluded that, due to the unlikelihood of realizing the value of that asset, it should be eliminated as of December 31, 2002. Finally, as a consequence of its review of its accounting with respect to its investment in Equistar, the Company elected to further amend its Consolidated Statements of Operations for the years 1998 through 2002 to reclassify to Selling, development and administrative expense various costs associated with its investment in Equistar and previously included in (Loss) earnings on Equistar investment in those Consolidated Statements of Operations.

A detailed discussion of the restatements of the Company's financial statements reflected in this amended Quarterly Report, including a summary of the aggregate effect of the changes implemented by the restatements, as well as the reclassification of costs associated with the Company's investment in Equistar, is set forth in Note 2 to the Consolidated Financial Statements included in this amended Quarterly Report. Changes also have been made to

2

the following additional items of the Quarterly Report on Form 10-Q as a result of the changes to the financial statements, principal among which are the following:

- o Item 1, Financial Statements, has been revised to reflect the restatements and the reclassification. In addition, the phrase "other environmental proceedings" has been deleted to reflect the fact that there are no environmental proceedings other than those involving environmental remediation activities;
- o Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations, has been revised to reflect the restatements and the reclassification; and
- o Item 4, Controls and Procedures, has been updated to reflect the evaluation made by the Company in connection with this Amendment.

This Amendment does not reflect events that have occurred after May 12, 2003, the date the Quarterly Report on Form 10-Q was originally filed. Information with respect to those events has been or will be set forth, as appropriate, in the Company's Quarterly Reports on Form 10-Q for the three-month periods ended June 30, 2003 and September 30, 2003. On November 12, 2003, the Company filed with the Securities and Exchange Commission an amendment to its Annual Report on Form 10-K for the year ended December 31, 2002 to reflect changes therein required as a consequence of the above-described financial statement restatements and reclassification and adjustments to its prior

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

financial statements for the timing of income and expense recognition associated with legal, environmental and other reserves established for certain of the Company's predecessor businesses, as more fully described in such amendment to the Company's Annual Report on Form 10-K. These adjustments for the timing of income and expense recognition did not change any of the financial information presented in the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2003 as filed on May 12, 2003 and, accordingly, are not discussed in this Amendment.

### Disclosure Concerning Forward-Looking Statements

The statements in this Quarterly Report on Form 10-Q/A (the "Quarterly Report") that are not historical facts are, or may be deemed to be, "forward-looking statements" ("Cautionary Statements") as defined in the Private Securities Litigation Reform Act of 1995. Some of these statements can be identified by the use of forward-looking terminology such as "prospects," "outlook," "believes," "estimates," "intends," "may," "will," "should," "anticipates," "expects" or "plans," or the negative or other variation of these or similar words, or by discussion of trends and conditions, strategy or risks and uncertainties. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements in other filings that the Company makes with the Securities and Exchange Commission, in press releases or in oral statements made by or with the approval of one of its authorized executive officers.

These forward-looking statements are only present expectations as at the time of the original filing of the Company's Quarterly Report on Form 10-Q. Actual events or results may differ materially. Factors that could cause such a difference include:

- o the cyclical and volatility of the chemical industries in which the Company and Equistar Chemicals, LP ("Equistar") operate, particularly fluctuations in the demand for ethylene, its derivatives and acetyls and the sensitivity of these industries to capacity additions;
- o general economic conditions in the geographic regions where the Company and Equistar generate sales, and the impact of government regulation and other external factors, in particular, the events in the Middle East;
- o the ability of Equistar to distribute cash to its partners and uncertainties arising from the Company's shared control of Equistar and the Company's contractual commitments regarding possible future capital contributions to Equistar;
- o changes in the cost of energy and raw materials, particularly natural gas and ethylene, and the ability of the Company and Equistar to pass on cost increases to their customers;
- o the ability of raw material suppliers to fulfill their commitments;

- o the ability of the Company and Equistar to achieve their productivity improvement, cost reduction and working capital targets, and the occurrence of operating problems at manufacturing facilities of the

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

Company or Equistar;

- o risks of doing business outside the United States, including currency fluctuations;
- o the cost of compliance with the extensive environmental regulations affecting the chemical industry and exposure to liabilities for environmental remediation and other environmental matters relating to the Company's and Equistar's current and former operations;
- o pricing and other competitive pressures;
- o legal proceedings relating to present and former operations (including proceedings based on alleged exposure to lead-based paints and lead pigments, asbestos and other materials), ongoing or future tax audits, and other claims; and
- o the Company's substantial indebtedness and its impact on the Company's cash flow, business operations and ability to obtain additional financing.

A further description of these risks, uncertainties and other matters can be found in Exhibit 99.1 to the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2003, as initially filed with the Securities and Exchange Commission on May 12, 2003. Some of these Cautionary Statements are discussed in more detail in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Quarterly Report. Readers are cautioned not to place undue reliance on forward-looking or Cautionary Statements, which reflect management's opinions only as of the date hereof. The Company undertakes no obligation to update any forward-looking or Cautionary Statement. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on behalf of the Company are expressly qualified in their entirety by the Cautionary Statements in this Quarterly Report. Readers are advised to consult any further disclosures the Company may make on related subjects in subsequent 10-Q, 8-K and 10-K reports to the Securities and Exchange Commission.

In this Quarterly Report, references to the Company are to the Company and its consolidated subsidiaries, except as the context otherwise requires.

### Non-GAAP Financial Measures

Financial measures based on accounting principles generally accepted in the United States of America ("GAAP") are commonly referred to as GAAP financial measures. For this purpose, a non-GAAP financial measure is generally defined by the Securities and Exchange Commission as one that purports to measure historical or future financial performance, financial position, or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable GAAP measure. From time to time the Company discloses so-called non-GAAP financial measures, primarily EBITDA, Pro Forma EBITDA, Pro Forma Operating Income, Pro Forma Net Sales and Pro Forma Depreciation and Amortization. EBITDA represents income from operations before interest, taxes, depreciation and amortization, other income items, equity earnings and the cumulative effect of accounting changes. EBITDA is a key measure used by the banking and investing communities in their evaluation of economic performance. Accordingly, management believes that disclosure of EBITDA provides useful information to investors because it is frequently cited by financial analysts in evaluating companies' performance. Pro Forma EBITDA and Pro Forma Operating Income include the Company's underlying interest (29.5%) in Equistar's results. Pro Forma Net Sales and Pro Forma Depreciation and Amortization include net sales and depreciation and amortization, respectively, in accordance with GAAP together with the Company's underlying interest in Equistar's corresponding

Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

amounts. The Company believes this pro forma information provides useful information to investors regarding its underlying interest in Equistar. EBITDA and the pro forma measures identified above are not a measure of operating performance computed in accordance with GAAP and should not be considered as a substitute for GAAP measures. Additionally, these measures may not be comparable to similarly named measures of other companies.

The Company also periodically reports adjusted net or operating income (loss) or adjusted EBITDA, excluding certain items that are unusual in nature or not comparable from period to period and that are included in GAAP measures of earnings. Management believes that excluding these items generally helps investors to compare

operating performance between two periods. Such adjusted data is not reported without an explanation of the items that are excluded.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

MILLENNIUM CHEMICALS INC.  
CONSOLIDATED BALANCE SHEETS  
(Millions, except share data)

| ASSETS                                   |    |
|--|----|
| Current assets                           |    |
| Cash and cash equivalents .....          | \$ |
| Trade receivables, net .....             |    |
| Inventories .....                        |    |
| Other current assets .....               |    |
| Total current assets .....               |    |
| Property, plant and equipment, net ..... |    |
| Investment in Equistar .....             |    |
| Other assets .....                       |    |
| Goodwill .....                           |    |

Mar  
2  
----  
(Res  
See  
(Una

Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

|   |     |
|---|-----|
| Total assets .....  | \$2 |
| =====   |     |
| LIABILITIES AND SHAREHOLDERS' DEFICIT   |     |
| Current liabilities   |     |
| Notes payable .....   | \$  |
| Other short-term borrowings .....   |     |
| Current maturities of long-term debt .....  |     |
| Trade accounts payable .....  |     |
| Income taxes payable .....  |     |
| Accrued expenses and other liabilities .....  |     |
| -----   |     |
| Total current liabilities .....   |     |
| Long-term debt .....  | 1   |
| Deferred income taxes .....   |     |
| Other liabilities .....   |     |
| -----   |     |
| Total liabilities .....   | 2   |
| Commitments and contingencies (Note 10)   |     |
| Minority interest .....   |     |
| Shareholders' deficit   |     |
| Preferred stock (par value \$.01 per share, authorized 25,000,000 shares, none issued and outstanding) .....                                    |     |
| Common stock (par value \$.01 per share, authorized 225,000,000 shares; issued 77,896,586 shares at March 31, 2003 and December 31, 2002) ..... | 1   |
| Paid in capital .....   |     |
| Accumulated deficit .....   |     |
| Cumulative other comprehensive loss .....   |     |
| Treasury stock, at cost (14,456,833 and 14,766,279 shares at March 31, 2003 and December 31, 2002, respectively) .....                          |     |
| Deferred compensation .....   |     |
| -----   |     |
| Total shareholders' deficit .....   |     |
| -----   |     |
| Total liabilities and shareholders' deficit .....   | \$2 |
| =====   |     |

See Notes to Consolidated Financial Statements.

MILLENNIUM CHEMICALS INC.  
CONSOLIDATED STATEMENTS OF OPERATIONS  
(UNAUDITED)  
(Millions, except per share data)

|  |                                |
|--|--------------------------------|
|  | Three Months En<br>March 31,   |
|  | -----                          |
|  | 2003                      2    |
|  | -----                          |
|  | (Restated -              (Rest |
|  | See Note 2)              See N |

Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

|   |           |       |
|---|-----------|-------|
| Net sales .....   | \$ 415    | \$    |
| Operating costs and expenses  |           |       |
| Cost of products sold .....   | 331       |       |
| Depreciation and amortization .....   | 27        |       |
| Selling, development and administrative expense .....   | 30        |       |
|   | -----     | ----  |
| Operating income .....  | 27        |       |
| Interest expense .....  | (23)      |       |
| Interest income .....   | 1         |       |
| Loss on Equistar investment .....   | (43)      |       |
| Other expense, net .....  | --        |       |
|   | -----     | ----  |
| Loss before income taxes, minority interest and cumulative effect<br>of accounting change ..... | (38)      |       |
| Benefit from income taxes .....   | 15        |       |
|   | -----     | ----  |
| Loss before minority interest and cumulative effect of accounting change...                     | (23)      |       |
| Minority interest .....   | (3)       |       |
|   | -----     | ----  |
| Loss before cumulative effect of accounting change .....  | (26)      |       |
| Cumulative effect of accounting change .....  | (1)       | (     |
|   | -----     | ----  |
| Net loss .....  | \$ (27)   | \$ (  |
|   | =====     | ====  |
| Basic and diluted loss per share:   |           |       |
| Before cumulative effect of accounting change .....   | \$ (0.41) | \$ (0 |
| From cumulative effect of accounting change .....   | (0.02)    | (4    |
|   | -----     | ----  |
| After cumulative effect of accounting change .....  | \$ (0.43) | \$ (5 |
|   | =====     | ====  |

See Notes to Consolidated Financial Statements.

7

MILLENNIUM CHEMICALS INC.  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
(UNAUDITED)  
(Millions)

|   | Three Mon   |
|---|-------------|
|   | March       |
|   | -----       |
|   | 2003        |
|   | -----       |
|   | (Restated   |
|   | See Note 2) |
| Cash flows from operating activities:                                       |             |
| Net loss.....   | \$ (27)     |
| Adjustments to reconcile net loss to net cash used in operating activities: |             |
| Cumulative effect of accounting change.....                                 | 1           |



Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

|   |       |
|---|-------|
| Depreciation and amortization.....  | 27    |
| Deferred income tax benefit .....   | (21)  |
| Loss on Equistar investment.....  | 43    |
| Minority interest.....  | 3     |
| Other, net.....   | (2)   |
| Changes in assets and liabilities:  |       |
| (Increase) decrease in trade receivables.....   | (13)  |
| Decrease in inventories.....  | 18    |
| Decrease (increase) in other current assets.....  | 1     |
| Increase in other assets.....   | --    |
| Decrease in trade accounts payable.....   | (36)  |
| Increase (decrease) in accrued expenses and other liabilities and income taxes payable..... | 4     |
| Decrease in other liabilities.....  | (12)  |
|   | ----  |
| Cash used in operating activities.....  | (14)  |
|   | ----  |
| Cash flows from investing activities:   |       |
| Capital expenditures.....   | (8)   |
|   | ----  |
| Cash used in investing activities.....  | (8)   |
|   | ----  |
| Cash flows from financing activities:   |       |
| Dividends to shareholders.....  | (9)   |
| Proceeds from long-term debt.....   | 96    |
| Repayment of long-term debt.....  | (66)  |
| (Decrease) increase in notes payable.....   | (1)   |
|   | ----  |
| Cash provided by financing activities.....  | 20    |
|   | ----  |
| Effect of exchange rate changes on cash.....  | 2     |
|   | ----  |
| Decrease in cash and cash equivalents.....  | --    |
| Cash and cash equivalents at beginning of year.....   | 125   |
|   | ----  |
| Cash and cash equivalents at end of period.....   | \$125 |
|   | ====  |

See Notes to Consolidated Financial Statements.

MILLENNIUM CHEMICALS INC.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)  
(Dollars in millions, except share data)

Note 1 - Basis of Presentation

Pursuant to the rules and regulations of the Securities and Exchange Commission, the accompanying unaudited interim consolidated financial statements do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America for complete financial statements. The accompanying consolidated financial statements should be read in conjunction with the financial statements and disclosures included in the Company's Annual Report on Form 10-K, as amended, for the year ended December

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

31, 2002. In the opinion of management, the accompanying consolidated financial statements contain all adjustments necessary to present fairly the financial position and results of operations for the interim periods.

The consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries. Minority interest represents the minority ownership of the Company's Brazilian subsidiary and the La Porte Methanol Company. All significant intercompany accounts and transactions have been eliminated. The Company's 29.5% investment in Equistar, a joint venture between the Company and Lyondell Chemical Company ("Lyondell"), is accounted for by the equity method; accordingly, the Company's share of Equistar's pre-tax net income or loss is included in net income or loss. Certain prior year balances have been reclassified to conform to the current year presentation, principally \$2 of selling, development and administrative ("S,D&A") costs allocated to the Company's investment in Equistar and previously reported in Loss on Equistar investment for each of the three months ended March 31, 2003 and 2002 have been reclassified to Selling, development and administrative expense in the Company's Consolidated Statements of Operations.

### Note 2 - Restatement of Financial Statements

The Company restated its financial statements for the years 1998 through 2002 and for the first quarter of 2003, to correct errors in its accounting for deferred taxes relating to its Equistar investment, the calculation of its pension benefit obligations and its accounting for a multi-year precious metals agreement. The Company's independent auditors, PricewaterhouseCoopers LLP ("PwC"), concur with the Company's decision to restate its financial statements.

Deferred tax assets and liabilities and deferred tax expense for the years 1998 through 2002 and for the first quarter of 2003 were restated to appropriately account for the Company's book and tax basis differences associated with its investment in Equistar in accordance with Statement of Financial Accounting Standards ("SFAS") No. 109, "Accounting for Income Taxes" ("SFAS No. 109"). The accounting for deferred taxes associated with Equistar was previously based on the difference between book and tax basis of a subsidiary that holds the partnership investment. Deferred tax is now based on the difference between book and tax basis of the actual partnership interest held by the subsidiary. The effect of the adjustments to deferred tax assets and liabilities was to increase net deferred tax liabilities by \$425, increase Accumulated deficit by \$440 and decrease Cumulative other comprehensive loss by \$15 at December 31, 2002. The effect of the adjustments to Benefit from income taxes for the three months ended March 31, 2003 was an increase of \$24, and for the three months ended March 31, 2002 was less than \$1. In addition, during the course of its review of its deferred taxes, the Company concluded that its realization of a deferred tax asset of \$10 related to its French subsidiaries was unlikely. The elimination of this deferred tax asset as of December 31, 2002 resulted in an increase of \$10 in net deferred tax liabilities and Accumulated deficit.

The Company's accrued pension benefit costs, included in Other liabilities, and its net periodic pension benefit cost were restated for 2002 and for the first quarter of 2003. The restatement corrected errors in the calculation of the Company's pension liability. The Company's principal actuarial firm incorrectly utilized participant data in its 2002 actuarial valuation and underestimated the accumulated pension benefit obligation at December 31, 2002 for the Company's largest domestic pension plan. The effect of these corrections was to increase accrued pension benefit cost by \$53, decrease net deferred tax liabilities by \$19, increase Accumulated deficit by \$1 and increase Cumulative other comprehensive loss by \$33 at December 31, 2002. The changes to net periodic pension benefit cost due to this restatement for the three months ended March 31, 2003 and 2002 were each less than \$1.

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

The Company also restated its financial statements for the years 1998 through 2002 and for the first quarter of 2003 due to a change in accounting treatment for a five-year agreement entered into in 1998 that provides the Company with the right to use gold owned by a third party, as more fully described in Note 7. The Company previously accounted for this agreement as an operating lease but is now accounting for this agreement as a secured financing. As a result, Other assets were increased by \$4, Current liabilities were increased by \$13, net deferred tax

9

MILLENNIUM CHEMICALS INC.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
(Dollars in millions, except share data)

liabilities were decreased by \$4, and Accumulated deficit was increased by \$5 at December 31, 2002. This restatement changed Operating income for the three months ended March 31, 2003 by less than \$1 and decreased Operating income for the three months ended March 31, 2002 by \$1. Net loss changed by less than \$1 for the three months ended March 31, 2003, and increased by \$1 for the three months ended March 31, 2002 as a result of this restatement.

A summary of the aggregate effect of these restatements and the reclassification described in Note 1 on the Company's Consolidated Balance Sheets and Consolidated Statements of Operations for the periods presented herein is shown below.

|  | March 31, 2003                       |             | Dec        |
|--|--------------------------------------|-------------|------------|
|  | As Reported                          | As Restated | As Repo    |
| Changes to Consolidated Balance Sheets:                  |                                      |             |            |
| Deferred income taxes - asset .....                      | \$ 75                                | \$ --       | \$         |
| Other assets .....                                       | 42                                   | 46          |            |
| Total assets .....                                       | 2,420                                | 2,349       | 2,4        |
| Other short-term borrowings .....                        | --                                   | 13          |            |
| Accrued expenses and other liabilities .....             | 132                                  | 132         | 1          |
| Total current liabilities .....                          | 427                                  | 440         | 4          |
| Deferred income taxes - liability .....                  | --                                   | 313         |            |
| Other liabilities .....                                  | 335                                  | 388         | 3          |
| Total liabilities .....                                  | 2,008                                | 2,387       | 2,0        |
| Accumulated deficit .....                                | (380)                                | (812)       | (3         |
| Cumulative other comprehensive loss .....                | (271)                                | (289)       | (2         |
| Total shareholders' equity (deficit) .....               | 389                                  | (61)        | 4          |
| Total liabilities and shareholders' equity (deficit) ... | 2,420                                | 2,349       | 2,4        |
|  | Three Months Ended<br>March 31, 2003 |             | Thre<br>Ma |
|  | As Reported                          | As Restated | As Repo    |

Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

|   | -----  | -----  | -----  |
|---|--------|--------|--------|
| Changes to Consolidated Statements of Operations:   |        |        |        |
| Cost of products sold .....   | \$ 330 | \$ 331 | \$ 293 |
| Selling, development and administrative expense .....   | 29     | 30     | 23     |
| Operating income .....  | 29     | 27     | 10     |
| Loss on Equistar investment .....   | (45)   | (43)   | (39)   |
| Loss before income taxes, minority interest and<br>cumulative effect of accounting change ..... | (38)   | (38)   | (51)   |
| (Provision for) benefit from income taxes .....   | (9)    | 15     | 20     |
| Loss before minority interest and cumulative effect of<br>accounting change .....               | (47)   | (23)   | (31)   |
| Loss before cumulative effect of accounting change ....   | (50)   | (26)   | (32)   |
| Net loss .....  | (51)   | (27)   | (337)  |
| Basic and diluted loss per share:   |        |        |        |
| Before cumulative effect of accounting change .....   | (0.78) | (0.41) | (0.50) |
| After cumulative effect of accounting change .....  | (0.80) | (0.43) | (5.30) |

10

MILLENNIUM CHEMICALS INC.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
(Dollars in millions, except share data)

Note 3 - Earnings per Share and Stock-Based Compensation

The weighted-average number of equivalent shares of common stock outstanding used in computing earnings per share is as follows:

|   | Three Months Ended<br>March 31, |                        |
|---|---------------------------------|------------------------|
|   | -----<br>2003<br>-----          | -----<br>2002<br>----- |
| Weighted-average common stock outstanding - basic and diluted ... | 63,852,822                      | 63,476,591             |
|   | =====                           | =====                  |

The calculation of diluted earnings per share for the three months ended March 31, 2003 does not include 53,957 restricted shares issued under a Company incentive plan, and 219,140 shares held by certain of the Company's employee benefit plan trusts. The calculation of diluted earnings per share for the three months ended March 31, 2002 does not include 91,740 options to purchase common stock, 78,944 restricted shares issued under a Company incentive plan, and 220,995 shares held by certain of the Company's employee benefit plan trusts. The effect of including these options and shares would be antidilutive.

SFAS No. 123 "Accounting for Stock-Based Compensation" ("SFAS No. 123") encourages a fair value based method of accounting for employee stock options and similar equity instruments, which generally would result in the recording of additional compensation expense in the Company's financial statements. SFAS No. 123 also allows the Company to continue to account for stock-based compensation

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

using the intrinsic value for equity instruments under Accounting Principles Board Opinion No. 25 ("APB Opinion No. 25"). The Company has elected to account for such instruments using APB Opinion No. 25 and related interpretations, and thus has adopted the disclosure-only provisions of SFAS No. 123. Accordingly, no compensation cost has been recognized for the stock option plans in the accompanying financial statements as all options granted had an exercise price equal to the market value of the underlying Common Stock on the date of grant.

Disclosure on a pro forma basis of net income and related per-share amounts as if the Company had applied the fair value recognition provisions of SFAS No. 123 to stock-based compensation is omitted because the effect on pro forma net income is not significant.

### Note 4 - Recent Accounting Developments

On January 1, 2003, the Company adopted SFAS No. 143, "Accounting for Asset Retirement Obligations" ("SFAS No. 143"). SFAS No. 143 applies to legal obligations associated with the retirement of long-lived assets. This standard requires that the fair value of a liability for an asset retirement obligation be recognized in the period in which it is incurred and the associated asset retirement costs be capitalized as part of the carrying amount of the long-lived asset. Accretion expense and depreciation expense related to the liability and capitalized asset retirement costs, respectively, are recorded in subsequent periods. The Company's asset retirement obligations arise from activities associated with the eventual remediation of sites used for landfills and mining and include estimated liabilities for closure, restoration, and post-closure care. None of the Company's assets are legally restricted for purposes of settling these obligations. The Company reported an after-tax transition charge of \$1 as the cumulative effect of this accounting change. The impact of adoption was insignificant to the Company's reported assets and liabilities. The ongoing annual expense resulting from the initial adoption of SFAS No. 143 is not expected to be significant. Activity associated with the asset retirement obligations other than the effect of initial adoption of SFAS No. 143 was not significant for the three months ended March 31, 2003. Disclosure on a pro forma basis of net income and related per-share amounts as if SFAS No. 143 had been applied during all periods presented is omitted because the effect on pro forma net income is not significant. The pro forma amount of the aggregate asset retirement obligation at March 31, 2003, January 1, 2003, March 31, 2002, and January 1, 2002, as if SFAS No. 143 had been applied during all periods affected is \$12, \$12, \$11, and \$11, respectively.

On January 1, 2002, the Company adopted SFAS No. 142, "Goodwill and Other Intangible Assets" ("SFAS No. 142"). Under this new standard, all goodwill, including goodwill acquired before initial application of the standard, is not amortized but must be tested for impairment at least annually at the reporting unit level, as defined in the standard. Accordingly, the Company reported a charge for the cumulative effect of this accounting change of \$275 in the first quarter of 2002 to write off certain of its goodwill related to its Acetyls business based upon the

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

Company's estimate of fair value for this business considering expected future profitability and cash flows. Also in accordance with SFAS No. 142, Equistar reported an impairment of its goodwill in the first quarter of 2002. The write-off at Equistar required an adjustment of \$30 to reduce the carrying value of the Company's investment in Equistar to its approximate proportional share of Equistar's Partners' capital.

### Note 5 - European Receivables Securitization Program

Since March 2002, the Company has been transferring its interest in certain European trade receivables to an unaffiliated third party as its basis for issuing commercial paper under a revolving securitization arrangement (annually renewable up to five years) with maximum availability of 70 million euro, which is treated, in part, as a sale under accounting principles generally accepted in the United States of America. Accordingly, transferred trade receivables that qualify as a sale, \$65 and \$61 outstanding at March 31, 2003 and December 31, 2002, respectively, are removed from the Company's Consolidated Balance Sheets. The Company continues to carry its retained interest in a portion of the transferred assets that do not qualify as a sale, \$10 and \$9 at March 31, 2003 and December 31, 2002, respectively, in Trade receivables, net in its Consolidated Balance Sheets at amounts that approximate net realizable value based upon the Company's historical collection rate for these trade receivables. Unused availability under this arrangement at March 31, 2003 was 1 million euro. For the three months ended March 31, 2003 and 2002, cumulative gross proceeds from this securitization arrangement were \$95 and \$43, respectively. Cash flows from this securitization arrangement are reflected as operating activities in the Consolidated Statements of Cash Flows. The cost of sale associated with this arrangement was \$1 for the three months ended March 31, 2003 and was not significant for the three months ended March 31, 2002. Administration and servicing of the trade receivables under the arrangement remains with the Company. Servicing liabilities associated with the transaction are not significant.

### Note 6 - Inventories

Inventories are stated at the lower of cost or market value.

|                                     | March 31,<br>2003 | December 31,<br>2002 |
|-------------------------------------|-------------------|----------------------|
|                                     | -----             | -----                |
| Finished products.....              | \$229             | \$210                |
| In-process products.....            | 29                | 30                   |
| Raw materials.....                  | 77                | 106                  |
| Maintenance parts and supplies..... | 58                | 60                   |
|                                     | ----              | ----                 |
|                                     | \$393             | \$406                |
|                                     | ====              | ====                 |

### Note 7 - Long-Term Debt and Credit Arrangements

In June 2002, the Company received approximately \$100 in net proceeds (\$102.5 in gross proceeds) from the completion of an offering by Millennium America Inc. ("Millennium America"), a wholly owned indirect subsidiary of the Company, of \$100 additional principal amount at maturity of 9.25% Senior Notes due June 15, 2008 (the "9.25% Senior Notes"). The gross proceeds of the offering were used to repay all outstanding borrowings at that time under the Company's revolving loan portion (the "Revolving Loans") of its five-year credit agreement

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

(the "Credit Agreement") and to repay \$65 outstanding under the term loan portion (the "Term Loans") of the Credit Agreement. The Company and Millennium America guarantee the obligations under the Credit Agreement.

The Company had \$56 outstanding (\$45 of outstanding borrowings and outstanding letters of credit of \$11) of the maximum available credit line of \$175 under the Revolving Loans and, accordingly, had \$119 of unused availability under such facility, and had \$48 outstanding under the Term Loans at March 31, 2003. In addition to letters of credit outstanding under the Credit Agreement, the Company had outstanding letters of credit under other arrangements of \$11 at March 31, 2003. The Company had unused availability under short-term uncommitted lines of credit, other than the Credit Agreement, of \$44 and \$34 at March 31, 2003 and April 30, 2003, respectively.

On April 25, 2003, the Company received approximately \$107 in net proceeds (\$109 in gross proceeds) from the completion of an offering by Millennium America of \$100 additional principal amount at maturity of the 9.25% Senior Notes. The proceeds of the offering were used to repay all of the \$85 of borrowings outstanding under the

12

### MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
(Dollars in millions, except share data)

Company's Revolving Loans and for general corporate purposes. At April 30, 2003, the Company had \$13 outstanding (no outstanding borrowings and outstanding letters of credit of \$13) under the Revolving Loans and, accordingly, had \$162 of unused availability under such facility, and had \$48 outstanding under the Term Loans. In addition to letters of credit outstanding under the Credit Agreement, the Company had outstanding letters of credit under other arrangements of \$11 at April 30, 2003.

The Revolving Loans are available in US dollars, British pounds and euros. The Revolving Loans may be borrowed, repaid and reborrowed from time to time. The Revolving Loans include a \$50 letter of credit subfacility and a swingline facility in the amount of \$25. As of March 31, 2003, \$11 was outstanding under the letter of credit subfacility, and no amount under the swingline facility. The Term Loans may be prepaid in part or in total at the option of the Company at any time, but any such amounts prepaid may not be reborrowed. The interest rates on the Revolving Loans and the Term Loans are floating rates based upon margins over LIBOR, NIBOR, or the Administrative Agent's prime lending rate, as the case may be. Such margins, as well as the facility fee, are based on the Company's Leverage Ratio, as defined.

The Credit Agreement contains various restrictive covenants and requires that the Company meet certain financial performance criteria. Compliance with these covenants is monitored frequently in order to assess the likelihood of continued compliance. The Company was in compliance with all covenants under the Credit Agreement in effect at March 31, 2003. Due to its expectation that it would not be in compliance at June 30, 2003, the Company obtained an amendment to the Credit Agreement on April 25, 2003, which amended the Leverage Ratio and Interest Coverage Ratio, each as defined in the Credit Agreement, as described below.

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

The financial covenants in the Credit Agreement include a Leverage Ratio and an Interest Coverage Ratio. The Leverage Ratio is the ratio of Total Indebtedness to cumulative EBITDA for the prior four fiscal quarters, each as defined. The Interest Coverage Ratio is the ratio of cumulative EBITDA for the prior four fiscal quarters to Net Interest Expense, for the same period, each as defined. To permit the Company to be in compliance, these covenants were amended in the fourth quarter of 2001, in the second quarter of 2002, and in the second quarter of 2003. The amendment in the second quarter of 2002 was conditioned upon consummation of the offering of \$100 additional principal amount of the 9.25% Senior Notes and retirement of the Credit Agreement debt described above. The latest amendment was not conditioned on the sale of 9.25% Senior Notes. Under the covenants, as amended in April of 2003, the Company is required to maintain a Leverage Ratio of no more than 5.75 to 1.00 for the second quarter of 2003; 5.50 to 1.00 for the third quarter of 2003; 5.25 to 1.00 for the fourth quarter of 2003; 5.00 to 1.00 for the first and second quarters of 2004; 4.75 to 1.00 for the third and fourth quarters of 2004; and 4.00 to 1.00 for the first quarter of 2005 and thereafter; and an Interest Coverage Ratio of no less than 2.25 to 1.00 for the second, third and fourth quarters of 2003; 2.50 to 1.00 for the first, second, third and fourth quarters of 2004; and 3.00 to 1.00 for the first quarter of 2005 and thereafter. The covenants in the Credit Agreement also limit, among other things, the ability of the Company and/or certain subsidiaries of the Company to: (i) incur debt and issue preferred stock; (ii) create liens; (iii) engage in sale/leaseback transactions; (iv) declare or pay dividends on, or purchase, the Company's stock; (v) make restricted payments; (vi) engage in transactions with affiliates; (vii) sell assets; (viii) engage in mergers or acquisitions; (ix) engage in domestic accounts receivable securitization transactions; and (x) enter into restrictive agreements. In the event the Company sells certain assets as specified in the Credit Agreement, the Term Loans must be prepaid with a portion of the net cash proceeds of such sale. The obligations under the Credit Agreement are collateralized by: (1) a pledge of 100% of the stock of the Company's existing and future domestic subsidiaries and 65% of the stock of certain of the Company's existing and future foreign subsidiaries, in both cases other than subsidiaries that hold immaterial assets (as defined in the Credit Agreement); (2) all the equity interests held by the Company's subsidiaries in Equistar and the La Porte Methanol Company (which pledges are limited to the right to receive distributions made by Equistar and the La Porte Methanol Company, respectively); and (3) all present and future accounts receivable, intercompany indebtedness and inventory of the Company's domestic subsidiaries, other than subsidiaries that hold immaterial assets.

Millennium America also has outstanding \$500 aggregate principal amount of 7.00% Senior Notes due November 15, 2006 (the "7.00% Senior Notes") and \$250 aggregate principal amount of 7.625% Senior Debentures due November 15, 2026 (the "7.625% Senior Debentures") that are fully and unconditionally guaranteed by the Company. The indenture under which the 7.00% Senior Notes and 7.625% Senior Debentures were issued contains certain covenants that limit, among other things: (i) the ability of Millennium America and its Restricted Subsidiaries (as defined) to grant liens or enter into sale/leaseback transactions; (ii) the ability of the Restricted Subsidiaries to incur additional indebtedness; and (iii) the ability of Millennium America and the Company to merge, consolidate or transfer substantially all of their respective assets. This indenture allows the Company to



## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
(Dollars in millions, except share data)

grant security on loans of up to 15% of Consolidated Net Tangible Assets ("CNTA"), as defined, of Millennium America. Accordingly, based upon CNTA and secured borrowing levels at March 31, 2003, any reduction in CNTA below approximately \$1,600 would decrease the Company's availability under the Revolving Loans by 15% of any such reduction.

The 9.25% Senior Notes were issued by Millennium America and are guaranteed by the Company. The indenture under which the 9.25% Senior Notes were issued contains certain covenants that limit, among other things, the ability of the Company and/or certain subsidiaries of the Company to: (i) incur additional debt; (ii) issue redeemable stock and preferred stock; (iii) create liens; (iv) redeem debt that is junior in right of payment to the 9.25% Senior Notes; (v) sell or otherwise dispose of assets, including capital stock of subsidiaries; (vi) enter into arrangements that restrict dividends from subsidiaries; (vii) enter into mergers or consolidations; (viii) enter into transactions with affiliates; and (ix) enter into sale/leaseback transactions. In addition, this indenture contains a covenant that would prohibit the Company from (i) paying dividends or making distributions on its common stock; (ii) repurchasing its common stock; and (iii) making other types of restricted payments, including certain types of investments, if such restricted payments would exceed a "restricted payments basket." The basket is reduced by the amount of each such restricted payment and is increased by: (i) 50% of the Company's Cumulative Net Income (as defined in such indenture) since July 1, 2001 (or is reduced by 100% of its Cumulative Net Income if such amount is negative); (ii) the net cash proceeds from the sale by the Company of its common stock to third parties; and (iii) 50% of any cash distributions received from Equistar. As of May 12, 2003, the date of filing of the original Quarterly Report on Form 10-Q, and after taking into consideration the restatements and reclassification in this Form 10-Q/A, the amount of the restricted payments basket is \$12 and includes results through March 31, 2003. The indenture also requires the calculation of a Consolidated Coverage Ratio, defined as the ratio of the aggregate amount of EBITDA, as defined, for the four most recent fiscal quarters to Consolidated Interest Expense, as defined, for the four most recent quarters. If this ratio were to cease to be greater than 2.00 to 1.00 (2.25 to 1.00 after June 15, 2003), there would be certain restrictions on the Company's ability to incur additional indebtedness and pay dividends, repurchase capital stock or make certain other restricted payments. However, if the 9.25% Senior Notes were to receive investment grade credit ratings from both Standard & Poor's ("S&P") and Moody's Investor Services, Inc. ("Moody's") and meet certain other requirements as specified in the indenture, certain of these covenants would no longer apply.

At March 31, 2003, the Company was in compliance with all covenants in the indentures governing the 9.25% Senior Notes, 7.00% Senior Notes and 7.625% Senior Debentures.

The Company is currently rated BB+ by S&P and Ba1 by Moody's, which are both non-investment grade ratings. On March 7, 2003, S&P lowered the Company's credit rating from investment grade rating BBB- to non-investment grade rating BB+ with a negative outlook, reflecting S&P's concern regarding the Company's ability to generate the cash flow necessary to substantially improve its financial profile during a period of economic uncertainties and higher raw material costs. Moody's affirmed the Company's non-investment grade rating on June 19, 2002, but revised its ratings outlook to negative from stable, reflecting Moody's concern over the Company's cash flow performance in the fourth quarter of 2001 and the first quarter of 2002. As a result of the non-investment grade rating by both S&P and Moody's, the Company was required to provide in April of 2003 a \$2.5 letter of credit in accordance with a real estate lease, which resulted in an equal reduction of availability under the Revolving Loans. Furthermore, the Company could be required to cash

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

collateralize the mark-to-market positions of certain derivative instruments dependent upon the market value of these instruments. Based on the current market value of the instruments, the Company is not required to place any funds on deposit with the counterparty to these transactions.

The Company uses gold as a component in a catalyst in the Company's La Porte, Texas facility. In April 1998, the Company entered into an agreement that provides the Company with the right to use gold owned by a third party for a five-year term. As a result of a change in accounting for this agreement, the Company's financial statements were restated as more fully described in Note 2. In April 2003, the Company renewed this agreement for a one-year term. The renewed agreement requires the Company to either deliver the gold to the counterparty at the end of the term or pay to the counterparty an amount equal to its then-current value. The renewed agreement provides that if the Company is downgraded below BB by S&P or Ba2 by Moody's, the third party could require the Company to purchase the gold at its then-current value. The value of the gold and the Company's obligation under this agreement was \$13 and \$14 at March 31, 2003 and December 31, 2002, respectively. The Company's obligation under this agreement is included in Other short-term borrowings. The change in value of the gold and the Company's obligation under this agreement, which is included in Selling, development and administrative expense,

14

### MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
(Dollars in millions, except share data)

was a gain of \$1 for the three months ended March 31, 2003, and a loss of \$1 for the three months ended March 31, 2002. In April 2003, the Company entered into a forward purchase agreement in order to mitigate the risk of change in the market price of gold.

#### Note 8 - Derivative Instruments and Hedging Activities

The Company is exposed to market risk, such as changes in currency exchange rates, interest rates and commodity pricing. To manage the volatility relating to these exposures, the Company selectively enters into derivative transactions pursuant to the Company's policies for hedging practices. Designation is performed on a specific exposure basis to support hedge accounting. The changes in fair value of these hedging instruments are offset in part or in whole by corresponding changes in the fair value or cash flows of the underlying exposures being hedged. The Company does not hold or issue derivative financial instruments for speculative or trading purposes.

**Foreign Currency Exposure Management:** The Company manufactures and sells its products in a number of countries throughout the world and, as a result, is exposed to movements in foreign currency exchange rates. The primary purpose of the Company's foreign currency hedging activities is to manage the volatility associated with foreign currency purchases and foreign currency sales. The Company utilizes forward exchange contracts with various terms. As of March 31, 2003, these contracts had expiration dates no later than March 31, 2004.

The Company utilizes forward exchange contracts with contract terms normally lasting less than three months to protect against the adverse effect that exchange rate fluctuations may have on foreign currency denominated trade

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

receivables and trade payables. These derivatives have not been designated as hedges for accounting purposes. The gains and losses on both the derivatives and the foreign currency denominated trade receivables and payables are recorded in current earnings. Net amounts included in earnings, which offset similar amounts from foreign currency denominated trade receivables and payables, were not significant in the three months ended March 31, 2003 and were losses of \$2 in the three months ended March 31, 2002.

In addition, the Company utilizes forward exchange contracts that qualify as cash flow hedges. These are intended to offset the effect of exchange rate fluctuations on forecasted sales and inventory purchases. Gains and losses on these instruments are deferred in other comprehensive income ("OCI") until the underlying transaction is recognized in earnings. The earnings impact is reported either in Net sales or Cost of products sold to match the underlying transaction being hedged. Net amounts on forward exchange contracts designated as cash flow hedges reclassified to earnings to match the gain or loss on the underlying transaction being hedged were insignificant for the three months ended March 31, 2003 and 2002. Hedge ineffectiveness had no significant impact on earnings for the first quarter of 2003 and 2002. No forward exchange contract cash flow hedges were discontinued during the first quarter of 2003 and 2002. The Company estimates that net losses of approximately \$6 (\$4 net of tax) on foreign currency cash flow hedges included in OCI at March 31, 2003 will be reclassified to earnings during the next twelve months.

**Commodity Price Risk Management:** Raw materials used by the Company are subject to price volatility caused by demand and supply conditions and other unpredictable factors. The Company selectively uses commodity swap arrangements and commodity options to manage the volatility related to anticipated purchases of natural gas with various terms. As of March 31, 2003, these instruments had expiration dates no later than January 2004. Certain of these market instruments are designated as cash flow hedges. The mark-to-market gain or loss on qualifying hedges is included in OCI to the extent effective, and reclassified into Cost of products sold in the period during which the hedged transaction affects earnings. The mark-to-market gains or losses on ineffective portions of hedges are recognized in Cost of products sold immediately. During the three months ended March 31, 2003 and 2002, net gains of \$1 and net losses of \$2, respectively, on commodity swaps designated as cash flow hedges were reclassified to Cost of products sold to match the gain on the underlying transaction being hedged. Hedge ineffectiveness had no significant impact on loss for the first quarter of 2003 and 2002. Net gains on commodity swap cash flow hedges that were discontinued in the first quarter of 2003 were insignificant and no commodity swap cash flow hedges were discontinued in 2002. The Company estimates that net gains on commodity swaps included in OCI at March 31, 2003 that will be reclassified to earnings during the next twelve months will not be significant.

MILLENNIUM CHEMICALS INC.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
(Dollars in millions, except share data)

In addition, the Company utilizes commodity swap and option arrangements to manage the volatility related to anticipated purchases of certain commodities, a portion of which exposes the Company to natural gas price risk. These derivatives have not been designated as hedges for accounting purposes. The

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

gains and losses on these market instruments are recorded in current earnings. Net gains included in earnings were not significant in the three months ended March 31, 2003.

**Interest Rate Risk Management:** The Company selectively uses derivative instruments to manage its ratio of debt bearing fixed interest rates to debt bearing variable interest rates. At March 31, 2003, the Company had outstanding interest rate swap agreements with a notional amount of \$225, which are designated as fair value hedges of underlying fixed-rate obligations. The fair value of these interest rate swap agreements was approximately \$5 at March 31, 2003 resulting in an increase to long-term debt carrying value and the recognition of a corresponding swap asset. The gains and losses on both the interest rate swaps and the hedged portion of the underlying debt are recorded in Interest expense. In addition, at March 31, 2003, the Company had outstanding an interest forward rate agreement with a notional amount of \$50, which is designated as a cash flow hedge of outstanding variable rate debt. The Company also had interest forward rate agreements with a notional amount of \$100, which have not been designated as hedges for accounting purposes. The gains and losses on these derivatives are recorded in the current period in interest expense. The fair value of these interest rate swap agreements was not significant at March 31, 2003. Hedge ineffectiveness had no significant impact on earnings for the first quarter of 2003 and 2002.

### Note 9 - Comprehensive Loss

The following table sets forth the components of other comprehensive income (loss) and total comprehensive loss:

|   | Three Months Ended<br>March 31, |                            |
|---|---------------------------------|----------------------------|
|   | 2003                            | 2002                       |
|   | (Restated -<br>See Note 2)      | (Restated -<br>See Note 2) |
| Net loss.....   | \$ (27)                         | \$ (338)                   |
| Other comprehensive income (loss)                         |                                 |                            |
| Net (losses) gains on derivative financial instruments... | (3)                             | 5                          |
| Minimum pension liability adjustment.....                 | --                              | 1                          |
| Currency translation adjustment.....                      | 13                              | (1)                        |
|   | ----                            | ----                       |
| Total comprehensive loss.....                             | \$ (17)                         | \$ (333)                   |
|   | =====                           | =====                      |

### Note 10 - Commitments and Contingencies

**Legal and Environmental:** The Company and various Company subsidiaries are defendants in a number of pending legal proceedings relating to present and former operations. These include several proceedings alleging injurious exposure of plaintiffs to various chemicals and other materials on the premises of, or manufactured by, the Company's current and former subsidiaries. Typically, such proceedings involve claims made by many plaintiffs against many defendants in the chemical industry. Millennium Petrochemicals is one of a number of defendants in 80 active premises-based asbestos cases (i.e., where the alleged exposure to asbestos-containing materials was to employees of third-party contractors or subcontractors on the premises of certain facilities, and did not relate to any products manufactured or sold by the Company or any of its predecessors). Millennium Petrochemicals is also one of a number of defendants

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

in one inactive premises-based asbestos case where the court placed the claim on a formal registry for dormant claims, and for which no defense costs are being incurred. Millennium Petrochemicals is responsible for these premises-based cases as a result of its indemnification obligations under the Company's agreements with Equistar; however, Equistar will be required to indemnify Millennium Petrochemicals for any such claims filed on or after December 1, 2004 related to the assets or businesses contributed by Millennium Petrochemicals to Equistar. Various other Company subsidiaries and alleged former subsidiaries are among a number of defendants in 50 active premises-based asbestos cases. The Company believes that it has valid defenses to these proceedings and is defending them vigorously. However, litigation is subject to uncertainties and the Company is unable to guarantee the outcome of these proceedings. In addition, the Company is subject to known

16

MILLENNIUM CHEMICALS INC.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
(Dollars in millions, except share data)

liabilities as to which it is currently not possible to make an estimate, and may be subject to potential unknown liabilities associated with its present and former operations, including environmental liabilities, arising from the operations of its predecessors and prior owners or operators of its sites or operations for which it may be responsible.

Together with other alleged past manufacturers of lead-based paint and lead pigments for use in paint, the Company, a current subsidiary, as well as alleged predecessor companies, have been named as defendants in various legal proceedings alleging that they and other manufacturers are responsible for personal injury, property damage, and remediation costs allegedly associated with the use of these products. The plaintiffs in these legal proceedings include municipalities, counties, school districts, individuals and the State of Rhode Island, and seek recovery under a variety of theories, including negligence, failure to warn, breach of warranty, conspiracy, market share liability, fraud, misrepresentation and public nuisance. Legal proceedings relating to lead pigment or paint are in various procedural stages or pre-trial, post-trial and post-dismissal settings.

One proceeding relating to lead pigment or paint was tried in 2002. On October 29, 2002, after a trial in which the jury deadlocked, the court in the State of Rhode Island v. Lead Industry Association, Inc., et al, commenced in the Superior Court of Providence, Rhode Island, on October 13, 1999, declared a mistrial. The sole issue before the jury in this phase of the proceeding was whether lead pigment in paint in and on public and private Rhode Island buildings constitutes a "public nuisance." On March 20, 2003, the court denied the motions for the judgment as a matter of law filed by both sides during and after the trial. The State of Rhode Island may seek a new trial.

There are eleven pending legal proceedings relating to lead pigment or paint in various pre-trial stages. There are three pending legal proceedings relating to lead pigment or paint that were dismissed after summary judgment was granted by the court in favor of the defendants, but are now pending appeal. There are four legal proceedings relating to lead pigment or paint which have been voluntarily dismissed by the plaintiffs. There is also one legal proceeding relating to lead pigment or paint that was dismissed after summary judgment was

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

granted by the court in favor of the defendants, but which has not been appealed. There are four legal proceedings relating to lead pigment or paint that were abated under the laws of the State of Texas pending the resolution of an appeal in another legal proceeding involving lead pigment or paint where summary judgment was granted by the court in favor of one defendant. During the abatement period, expected to last one to two years, no defense costs will be incurred for the abated legal proceedings. Finally, there are six legal proceedings relating to lead pigment or paint that have been filed with a court, are pending, but have yet to be formally served on the Company, any of its subsidiaries, or alleged predecessor companies.

The Company's defense costs to date for lead-based paint and lead pigment litigation largely have been covered by insurance. The Company has not accrued any liabilities for any lead-based paint and lead pigment litigation. The Company has insurance policies that potentially provide approximately one billion dollars in indemnity coverage for lead-based paint and lead pigment litigation. As a result of insurance coverage litigation initiated by the Company, an Ohio trial court issued a decision in 2002 effectively requiring certain insurance carriers to resume paying defense costs in the lead-based paint and lead pigment cases. Indemnity coverage was not at issue in the Ohio court's decision. The insurance carriers may appeal the Ohio decision regarding defense costs, and they have in the past and may in the future attempt to deny indemnity coverage if there is ever a settlement or an adverse judgment in any lead-based paint or lead pigment case.

In 1986, a predecessor of a company that is now a subsidiary of the Company sold its recently acquired Glidden Paints business. As part of that sale, the seller agreed to indemnify the purchaser against certain claims made during the first eight years after the sale; the purchaser agreed to indemnify the seller against such claims made after the eight-year period. With the exception of the two cases discussed below, all pending lead-based paint and lead pigment litigation involving the Company and its subsidiaries, including the Rhode Island case, was filed after the eight-year period. Accordingly, the Company believes that it is entitled to full indemnification from the purchaser against lead-based paint and lead pigment cases filed after the eight-year period. The purchaser disputes that it has such an indemnification obligation, and claims that the seller must indemnify it. Since the Company's defense costs to date largely have been covered by insurance and there never has been a settlement paid by, nor any judgment rendered against, the Company (or any other company sued in any lead-based paint or lead pigment litigation), the parties' indemnification claims have not been ruled on by a court.

17

MILLENNIUM CHEMICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
(Dollars in millions, except share data)

A current subsidiary and an alleged predecessor company are parties to the only two remaining cases originally filed within the eight-year period following the 1986 sale of the Glidden Paints business referred to above. In the first of these cases, *The City of New York, et al. v. Lead Industries Association, Inc., et al.*, commenced in the Supreme Court of the State of New York on June 8, 1989, the New York City Housing Authority brought an action relating to tens of thousands of public housing units. All claims in that case have been dropped except for those relating to two housing projects. The other remaining case,

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

Jackson, et al. v. The Glidden Co., et al., commenced in the Court of Common Pleas, Cuyahoga County, Ohio, on August 12, 1992, includes five minors as plaintiffs. Dispositive motions were filed in that case in late 2002 and have yet to be ruled on by the court.

The Company believes that it has valid defenses to all pending lead-based paint and lead pigment proceedings and is vigorously defending them. However, litigation is inherently subject to many uncertainties. There can be no assurance that additional lead-based paint and lead pigment litigation will not be filed against the Company or its subsidiaries in the future asserting similar or different legal theories and seeking similar or different types of damages and relief. While an outcome such as that reached in the Rhode Island proceeding may have a positive effect on the lead-based paint and lead pigment litigation against the Company, its subsidiaries and other defendants by reducing the number and nature of future claims and proceedings, other adverse court rulings or determinations of liability, among other factors, could encourage an increase in the number of future claims and proceedings. In addition, from time to time, legislation and administrative regulations have been enacted or proposed to impose obligations on present and former manufacturers of lead-based paint and lead pigment respecting asserted health concerns associated with such products or to overturn successful court decisions. Due to the uncertainties involved, the Company is unable to predict the outcome of lead-based paint and lead pigment litigation, the number or nature of possible future claims and proceedings, or the effect that any legislation and/or administrative regulations may have on the Company or its subsidiaries. In addition, management cannot reasonably estimate the scope or amount of the costs and potential liabilities related to such litigation, or any such legislation and regulations. Accordingly, the Company has not accrued any liabilities for such litigation. However, based upon, among other things, the outcome of such litigation to date, including the dismissal of most of the over 50 lawsuits brought in recent years, management does not currently believe that the costs or potential liabilities ultimately determined to be attributable to the Company arising out of such litigation will have a material adverse effect on the consolidated financial position, results of operations or cash flows of the Company.

The Company's businesses are subject to extensive federal, state, local and foreign laws, regulations, rules and ordinances concerning, among other things, emissions to the air, discharges and releases to land and water, the generation, handling, storage, transportation, treatment and disposal of wastes and other materials and the remediation of environmental pollution caused by releases of wastes and other materials (collectively, "Environmental Laws"). The operation of any chemical manufacturing plant and the distribution of chemical products entail risks under Environmental Laws, many of which provide for substantial fines and criminal sanctions for violations. There can be no assurance that significant costs or liabilities will not be incurred with respect to the Company's operations and activities. In particular, the production of  $TiO_2$ ,  $TiCl_4$ , VAM, acetic acid, methanol and certain other chemicals involves the handling, manufacture or use of substances or compounds that may be considered to be toxic or hazardous within the meaning of certain Environmental Laws, and certain operations have the potential to cause environmental or other damage. Significant expenditures including facility-related expenditures could be required in connection with any investigation and remediation of threatened or actual pollution, triggers under existing Environmental Laws tied to production or new requirements under Environmental Laws.

The Company cannot predict whether future developments or changes in laws and regulations concerning environmental protection will affect its earnings or cash flow in a materially adverse manner or whether its operating units, Equistar or La Porte Methanol Company will be successful in meeting future demands of regulatory agencies in a manner that will not materially adversely affect the consolidated financial position, results of operations or cash flows of the Company. For example, the Texas Commission on Environmental Quality (the

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

"TCEQ") submitted a plan to the United States Environmental Protection Agency ("EPA") requiring the eight-county Houston/Galveston, Texas area to come into compliance with the National Ambient Air Quality Standard for ozone by 2007. These requirements, if implemented, would mandate significant reductions of nitrogen oxide ("NOx") emissions requiring increased capital investment by Equistar of between \$200 and \$260 before the 2007 regulatory deadline, as well as create higher annual operating costs. This result could potentially affect cash distributions from Equistar to the Company. In January 2001, Equistar, individually and as part of an industry coalition, filed a lawsuit in State District Court in Travis County, Texas seeking adoption of an alternative plan for air quality improvement. In response to the lawsuit, the TCEQ conducted an accelerated scientific review during 2001 and 2002. In December

18

MILLENNIUM CHEMICALS INC.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
(Dollars in millions, except share data)

2002, the TCEQ adopted revised rules, which changed the required NOx emission reduction levels from 90% to 80% while requiring new controls on emissions of highly reactive volatile organic compounds ("HRVOCs"), such as ethylene, propylene, butadiene and butanes. These new rules still require approval by the EPA. Based on the 80% NOx reduction requirement, Equistar estimates that its aggregate related capital expenditures could total between \$165 and \$200 before the 2007 deadline, and could result in higher annual operating costs. Equistar is still assessing the impact of the new HRVOC control requirements. Additionally, the TCEQ plans to make a final review of these rules, with final rule revisions to be adopted by May 2004. The timing and amount of these expenditures are subject to regulatory and other uncertainties, as well as obtaining the necessary permits and approvals. At this time, there can be no guarantee as to the ultimate capital cost of implementing any final plan developed to ensure ozone attainment by the 2007 deadline.

From time to time, various agencies may serve cease and desist orders or notices of violation on an operating unit or deny its applications for certain licenses or permits, in each case alleging that the practices of the operating unit are not consistent with regulations or ordinances. In some cases, the relevant operating unit may seek to meet with the agency to determine mutually acceptable methods of modifying or eliminating the practice in question. On April 14, 2003, a subsidiary of the Company received Proposed Director's Final Findings and Orders from the Ohio Environmental Protection Agency (the "Ohio EPA"), for alleged violations of Ohio environmental regulations. The Ohio EPA proposed a penalty in the amount of one hundred seventy-five thousand dollars. The Company disputes the findings of the Ohio EPA. The Company and the Ohio EPA are currently negotiating a resolution of this matter. The Company believes that its operating units generally operate in compliance with applicable regulations and ordinances in a manner that should not have a material adverse effect on the consolidated financial position, results of operations or cash flows of the Company.

Certain Company subsidiaries have been named as defendants, potentially responsible parties (the "PRPs"), or both, in a number of environmental proceedings associated with waste disposal sites or facilities currently or previously owned, operated or used by the Company's current or former subsidiaries or their predecessors, some of which are on the Superfund National



## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

Priorities List of the EPA or similar state lists. These proceedings seek cleanup costs, damages for personal injury or property damage, or both. Based upon third-party technical reports, the projections of outside consultants or outside counsel, or both, the Company has estimated its individual exposure at these sites to be between ten thousand dollars and \$26. In the most significant of these proceedings, a subsidiary is named as one of four PRPs at the Kalamazoo River Superfund Site in Michigan. The site involves contamination of river sediments and floodplain soils with polychlorinated biphenyls. Originally commenced on December 2, 1987 in the United States District Court for the Western District of Michigan as *Kelly v. Allied Paper, Inc., et al.*, the matter was stayed and is being addressed under the Comprehensive Environmental Response, Compensation and Liability Act. In October 2000, the Kalamazoo River Study Group (the "KRSG"), of which one of the Company's subsidiaries is a member, submitted to the State of Michigan a Draft Remedial Investigation and Draft Feasibility Study (the "Draft Study"), which evaluated a number of remedial options and recommended a remedy involving the stabilization of several miles of river bank and the long-term monitoring of river sediments at a total collective cost of approximately \$73. During 2001, additional sampling activities were performed in discrete parts of the river. At the end of 2001, the EPA took responsibility for the site at the request of the State. While the State has submitted comments to the EPA on the Draft Study, the EPA has yet to similarly comment. The Company has estimated its liability at this site based upon the KRSG's recommended remedy. Guidance as to how the EPA will likely proceed with further evaluation and remediation, if required, at the Kalamazoo site is expected by early 2004. At that time, the Company's estimate of its liability will be reevaluated. The Company's ultimate liability for the Kalamazoo site will depend on many factors that have not yet been determined, including the ultimate remedy selected by the EPA, the number and financial viability of the other members of the KRSG as well as of other PRPs outside the KRSG, and the determination of the final allocation among the members of the KRSG and other PRPs.

The Company believes that the reasonably probable and estimable range of potential liability for environmental and other legal contingencies, collectively, but which primarily relates to environmental remediation activities, is between \$67 and \$90 and has accrued \$73 as of March 31, 2003. The Company expects that cash expenditures related to these potential liabilities will be made over a number of years, and will not be concentrated in any single year. This accrual also reflects the fact that certain Company subsidiaries have contractual obligations to indemnify other parties against certain environmental and other liabilities. For example, the Company agreed as part of its demerger (i.e., spin-off) from Hanson plc ("Hanson"), a company incorporated in the United Kingdom, on October 1, 1996 to indemnify Hanson and certain of its subsidiaries against certain of such contractual indemnification obligations, and Millennium Petrochemicals agreed as part of the December 1, 1997 formation of Equistar to indemnify Equistar for certain liabilities related to the assets contributed by Millennium Petrochemicals

MILLENNIUM CHEMICALS INC.  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
(Dollars in millions, except share data)

to Equistar in excess of \$7, which threshold was exceeded in 2001. The terms of these indemnification agreements do not limit the maximum potential future

Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

payments to the indemnified parties. The maximum amount of future indemnification payments is dependent upon many factors and is not practicable to estimate.

No assurance can be given that actual costs for environmental matters will not exceed accrued amounts or that estimates made with respect to indemnification obligations will be accurate. In addition, it is possible that costs will be incurred with respect to contamination, indemnification obligations or other environmental matters that currently are unknown or as to which it is currently not possible to make an estimate.

On January 16, 2002, Slidell Inc. ("Slidell") filed a lawsuit against Millennium Inorganic Chemicals Inc., a wholly owned operating subsidiary of the Company, alleging breach of contract and other related causes of action arising out of a contract between the two parties for the supply of packaging equipment. In the suit, Slidell seeks unspecified monetary damages. The Company believes it has substantial defenses to these allegations and has filed a counterclaim against Slidell.

The Company believes that it has valid defenses to the legal proceedings described above and intends to defend these legal proceedings vigorously. However, litigation is subject to many uncertainties and the Company cannot guarantee the outcome of these proceedings. Based upon information currently available, the Company does not believe that the outcome of these proceedings will, either individually or in the aggregate, have a material adverse effect on the consolidated financial position, results of operations or cash flows of the Company.

20

MILLENNIUM CHEMICALS INC.  
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
 (Dollars in millions, except share data)

Note 11 - Operations by Business Segment

The Company's principal operations are managed and grouped as three separate business segments: Titanium Dioxide and Related Products, Acetyls and Specialty Chemicals. Operating income and expense not identified with the three separate business segments, including certain of the Company's S,D&A costs not allocated to its three business segments, employee-related costs from predecessor businesses and certain other expenses, are reflected as Other. The following is a summary of the Company's operations by business segment:

|   | Three Months Ended<br>March 31,     |                                     |
|---|-------------------------------------|-------------------------------------|
|   | 2003                                | 2002                                |
|   | -----<br>(Restated -<br>See Note 2) | -----<br>(Restated -<br>See Note 2) |
| Net sales                                   |                                     |                                     |
| Titanium Dioxide and Related Products ..... | \$288                               | \$262                               |

Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

|   |           |              |
|---|-----------|--------------|
| Acetyls .....                               | 102       | 65           |
| Specialty Chemicals .....                   | 25        | 24           |
|   | ----      | ----         |
| Total .....                                 | \$415     | \$351        |
|   | =====     | =====        |
| Operating income (loss)                     |           |              |
| Titanium Dioxide and Related Products ..... | \$ 21     | \$ 10        |
| Acetyls .....                               | 7         | (8)          |
| Specialty Chemicals .....                   | 2         | 4            |
| Other .....                                 | (3)       | 1            |
|   | ----      | ----         |
| Total .....                                 | \$ 27     | \$ 7         |
|   | =====     | =====        |
| Depreciation and amortization               |           |              |
| Titanium Dioxide and Related Products ..... | \$ 22     | \$ 20        |
| Acetyls .....                               | 3         | 3            |
| Specialty Chemicals .....                   | 2         | 2            |
|   | ----      | ----         |
| Total .....                                 | \$ 27     | \$ 25        |
|   | =====     | =====        |
| Capital expenditures                        |           |              |
| Titanium Dioxide and Related Products ..... | \$ 7      | \$ 12        |
| Acetyls .....                               | --        | --           |
| Specialty Chemicals .....                   | 1         | 1            |
| Other .....                                 | --        | --           |
|   | ----      | ----         |
| Total .....                                 | \$ 8      | \$ 13        |
|   | =====     | =====        |
|   | March 31, | December 31, |
|   | 2003      | 2002         |
|   | -----     | -----        |
| Goodwill                                    |           |              |
| Titanium Dioxide and Related Products ..... | \$ 58     | \$ 58        |
| Acetyls .....                               | 48        | 48           |
|   | ----      | ----         |
| Total .....                                 | \$106     | \$106        |
|   | =====     | =====        |

21

MILLENNIUM CHEMICALS INC.  
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
 (Dollars in millions, except share data)

Note 12 - Information on Equistar

The following is summarized financial information for Equistar:

Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

|   | March 31,<br>2003 | December 31,<br>2002 |
|---|-------------------|----------------------|
|   | -----             | -----                |
| Current assets .....                          | \$1,180           | \$1,126              |
| Noncurrent assets .....                       | 3,863             | 3,926                |
|   | -----             | -----                |
| Total assets .....                            | \$5,043           | \$5,052              |
|   | =====             | =====                |
| Current liabilities .....                     | \$ 984            | \$ 714               |
| Noncurrent liabilities .....                  | 2,284             | 2,417                |
| Partners' capital .....                       | 1,775             | 1,921                |
|   | -----             | -----                |
| Total liabilities and partners' capital ..... | \$5,043           | \$5,052              |
|   | =====             | =====                |

|   | Three Months Ended<br>March 31, |          |
|---|---------------------------------|----------|
|   | 2003                            | 2002     |
|   | -----                           | -----    |
| Net sales .....   | \$1,641                         | \$ 1,136 |
| Operating loss .....  | (96)                            | (75)     |
| Loss before cumulative effect of accounting<br>change ..... | (146)                           | (126)    |
| Cumulative effect of accounting change .....                | --                              | (1,053)  |
| Net loss .....  | (146)                           | (1,179)  |

The Company recorded \$30 related to its share of Equistar's write-down of goodwill during the three months ended March 31, 2002. Even though the Company's share (i.e., 29.5%) of Equistar's write-down is higher than the amount recorded by the Company, most of the write-down was previously taken by the Company in 1999 when it wrote down its investment in Equistar by \$639.

On March 31, 2003, Equistar completed transactions involving a 15-year propylene supply arrangement and the sale of a polypropylene production facility in Pasadena, Texas. Equistar received total cash proceeds of approximately \$194, including the value of the polypropylene inventory sold. Approximately \$159 of the total cash proceeds represented a partial prepayment under the propylene supply arrangement.

In April 2003, Equistar completed a private placement of \$450 of 10.625% senior notes due in 2011. The proceeds, net of associated fees, are being used to prepay \$300 of 8.5% notes due in the first quarter of 2004, approximately \$122 of the \$296 of outstanding term loans under Equistar's credit facility and prepayment premiums of approximately \$17.

Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

MILLENNIUM CHEMICALS INC.  
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
 (Dollars in millions, except share data)

Note 13 - Supplemental Financial Information

Millennium America, a wholly owned indirect subsidiary of the Company, is a holding company for all of the Company's operating subsidiaries other than its operations in the United Kingdom, France, Brazil and Australia. Millennium America is the issuer of the 7% Senior Notes, the 7.625% Senior Debentures, and the 9.25% Senior Notes, and is the principal borrower under the Credit Agreement. Millennium America guarantees all obligations under the Credit Agreement. The 7% Senior Notes, the 7.625% Senior Debentures and the 9.25% Senior Notes, as well as outstanding amounts under the Credit Agreement, are guaranteed by the Company. Accordingly, the following Condensed Consolidating Balance Sheets at March 31, 2003 and December 31, 2002, and the Condensed Consolidating Statements of Operations and Cash Flows for each of the three month periods ended March 31, 2003 and 2002, are provided for the Company as supplemental financial information to the Company's consolidated financial statements to disclose the financial position, results of operations and cash flows of (i) the Company, (ii) Millennium America, and (iii) all subsidiaries of the Company other than Millennium America (the "Non-Guarantor Subsidiaries"). The investment in subsidiaries of Millennium America and the Company are accounted for by the equity method; accordingly, the shareholders' deficit of Millennium America and the Company are presented as if each of those companies and their respective subsidiaries were reported on a consolidated basis.

23

MILLENNIUM CHEMICALS INC.  
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
 (Dollars in millions, except share data)

Note 13 - Supplemental Financial Information - Continued

|  | Millennium<br>America Inc.<br>(Issuer) | Millennium<br>Chemicals Inc.<br>(Guarantor) | Non-Guarantor<br>Subsidiaries |
|--|--|---|-------------------------------|
|  | -----                                  | -----                                       | -----                         |
| March 31, 2003 (Restated - See Note 2)   |  |   |                               |
| ASSETS                                   |  |   |                               |
| Inventories .....                        | \$ --                                  | \$ --                                       | \$ 393                        |
| Other current assets .....               | 6                                      | --  | 426                           |
| Property, plant and equipment, net ..... | --                                     | --  | 852                           |
| Investment in Equistar .....             | --                                     | --  | 520                           |
| Investment in subsidiaries .....         | 287                                    | 78  | --                            |
| Other assets .....                       | 15                                     | --  | 31                            |
| Goodwill .....                           | --                                     | --  | 106                           |

Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

|   |         |       |         |
|---|---------|-------|---------|
| Due from parent and affiliates, net ..... | 701     | --    | --      |
|   | -----   | ----  | -----   |
| Total assets .....                        | \$1,009 | \$ 78 | \$2,328 |
|   | =====   | ===== | =====   |

LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY

|   |         |       |         |
|---|---------|-------|---------|
| Current maturities of long-term debt .....                    | \$ 3    | \$ -- | \$ 5    |
| Other current liabilities .....                               | 31      | --    | 401     |
| Long-term debt .....  | 1,230   | --    | 16      |
| Deferred income taxes .....                                   | --      | --    | 313     |
| Other liabilities .....                                       | --      | --    | 388     |
| Due to parent and affiliates, net .....                       | --      | 139   | 562     |
|   | -----   | ----- | -----   |
| Total liabilities .....                                       | 1,264   | 139   | 1,685   |
| Minority interest .....                                       | --      | --    | 23      |
| Shareholders' (deficit) equity .....                          | (255)   | (61)  | 620     |
|   | -----   | ----- | -----   |
| Total liabilities and shareholders' (deficit)<br>equity ..... | \$1,009 | \$ 78 | \$2,328 |
|   | =====   | ===== | =====   |

December 31, 2002 (Restated - See Note 2)

ASSETS

|   |         |       |         |
|---|---------|-------|---------|
| Inventories .....                         | \$ --   | \$ -- | \$ 406  |
| Other current assets .....                | 10      | --    | 403     |
| Property, plant and equipment, net .....  | --      | --    | 862     |
| Investment in Equistar .....              | --      | --    | 563     |
| Investment in subsidiaries .....          | 349     | 95    | --      |
| Other assets .....                        | 15      | --    | 31      |
| Goodwill .....                            | --      | --    | 106     |
| Due from parent and affiliates, net ..... | 638     | --    | --      |
|   | -----   | ----- | -----   |
| Total assets .....                        | \$1,012 | \$ 95 | \$2,371 |
|   | =====   | ===== | =====   |

LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY

|   |         |       |         |
|---|---------|-------|---------|
| Current maturities of long-term debt .....                    | \$ 3    | \$ -- | \$ 9    |
| Other current liabilities .....                               | 8       | --    | 455     |
| Long-term debt .....  | 1,196   | --    | 16      |
| Deferred income taxes .....                                   | --      | --    | 337     |
| Other liabilities .....                                       | --      | --    | 388     |
| Due to parent and affiliates, net .....                       | --      | 130   | 508     |
|   | -----   | ----- | -----   |
| Total liabilities .....                                       | 1,207   | 130   | 1,713   |
| Minority interest .....                                       | --      | --    | 19      |
| Shareholders' (deficit) equity .....                          | (195)   | (35)  | 639     |
|   | -----   | ----- | -----   |
| Total liabilities and shareholders' (deficit)<br>equity ..... | \$1,012 | \$ 95 | \$2,371 |
|   | =====   | ===== | =====   |

## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

MILLENNIUM CHEMICALS INC.  
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
 (Dollars in millions, except per share data)

### Note 13 - Supplemental Financial Information - Continued

|  | Millennium<br>America Inc.<br>(Issuer) | Millennium<br>Chemicals Inc.<br>(Guarantor) | Non-Guarantor<br>Subsidiaries |
|--|--|---|-------------------------------|
|  | -----                                  | -----                                       | -----                         |
| Three Months Ended March 31, 2003<br>(Restated - See Note 2) |  |   |                               |
| -----  |  |   |                               |
| Net sales.....   | \$ --                                  | \$ --                                       | \$ 415                        |
| Cost of products sold.....                                   | --                                     | --  | 331                           |
| Depreciation and amortization.....                           | --                                     | --  | 27                            |
| Selling, development and administrative expense...           | --                                     | --  | 30                            |
|  | -----                                  | -----                                       | -----                         |
| Operating income.....  | --                                     | --  | 27                            |
| Interest expense, net.....                                   | (22)                                   | --  | --                            |
| Intercompany interest income (expense), net.....             | 24                                     | (1)   | (23)                          |
| Loss on Equistar investment.....                             | --                                     | --  | (43)                          |
| Equity in loss of subsidiaries.....                          | (40)                                   | (26)  | -                             |
| Other expense, net.....                                      | --                                     | --  | (3)                           |
| Income taxes.....  | (1)                                    | --  | 16                            |
| Cumulative effect of accounting change.....                  | --                                     | --  | (1)                           |
|  | -----                                  | -----                                       | -----                         |
| Net loss.....  | \$ (39)                                | \$ (27)                                     | \$ (27)                       |
|  | =====                                  | =====                                       | =====                         |
| Three Months Ended March 31, 2002<br>(Restated - See Note 2) |  |   |                               |
| -----  |  |   |                               |
| Net sales.....   | \$ --                                  | \$ --                                       | \$ 351                        |
| Cost of products sold.....                                   | --                                     | --  | 293                           |
| Depreciation and amortization.....                           | --                                     | --  | 25                            |
| Selling, development and administrative expense...           | --                                     | --  | 26                            |
|  | -----                                  | -----                                       | -----                         |
| Operating income.....  | --                                     | --  | 7                             |
| Interest (expense) income, net.....                          | (22)                                   | --  | 1                             |
| Intercompany interest income (expense), net.....             | 27                                     | (1)   | (26)                          |
| Loss on Equistar investment.....                             | --                                     | --  | (37)                          |
| Equity in loss of subsidiaries.....                          | (347)                                  | (337)                                       | --                            |
| Other expense, net.....                                      | --                                     | --  | (2)                           |
| Income taxes.....  | (2)                                    | --  | 22                            |
| Cumulative effect of accounting change.....                  | --                                     | --  | (305)                         |
|  | -----                                  | -----                                       | -----                         |
| Net loss.....  | \$ (344)                               | \$ (338)                                    | \$ (340)                      |
|  | =====                                  | =====                                       | =====                         |

Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

MILLENNIUM CHEMICALS INC.  
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) -- (Continued)  
 (Dollars in millions, except per share data)

Note 13 - Supplemental Financial Information - Continued

|   | Millennium<br>America Inc.<br>(Issuer) | Millennium<br>Chemicals Inc.<br>(Guarantor) | Non-Guarantor<br>Subsidiaries |
|---|--|---|-------------------------------|
|   | -----                                  | -----                                       | -----                         |
| Three Months Ended<br>March 31, 2003<br>-----             |  |   |                               |
| Cash flows from operating activities .....                | \$ 25                                  | \$ (1)                                      | \$ (38)                       |
|   | ----                                   | ----  | ----                          |
| Cash flows from investing activities                      |  |   |                               |
| Capital expenditures .....                                | --                                     | --  | (8)                           |
|   | ----                                   | ----  | ----                          |
| Cash used in investing activities .....                   | --                                     | --  | (8)                           |
|   | ----                                   | ----  | ----                          |
| Cash flows from financing activities                      |  |   |                               |
| Dividends to shareholders .....                           | --                                     | (9)   | --                            |
| Proceeds from long-term debt .....                        | 95                                     | --  | 1                             |
| Repayment of long-term debt .....                         | (61)                                   | --  | (5)                           |
| Intercompany .....  | (64)                                   | 10  | 54                            |
| Decrease in notes payable .....                           | --                                     | --  | (1)                           |
|   | ----                                   | ----  | ----                          |
| Cash (used in) provided by financing<br>activities .....  | (30)                                   | 1   | 49                            |
|   | ----                                   | ----  | ----                          |
| Effect of exchange rate changes on cash .....             | --                                     | --  | 2                             |
|   | ----                                   | ----  | ----                          |
| (Decrease) increase in cash and cash<br>equivalents ..... | (5)                                    | --  | 5                             |
| Cash and cash equivalents at beginning of<br>year .....   | 6                                      | --  | 119                           |
|   | ----                                   | ----  | ----                          |
| Cash and cash equivalents at end of period .....          | \$ 1                                   | \$--  | \$124                         |
|   | ====                                   | ====  | ====                          |
| Three Months Ended<br>March 31, 2002<br>-----             |  |   |                               |
| Cash flows from operating activities .....                | \$ 18                                  | \$ (2)                                      | \$ (49)                       |
|   | ----                                   | ----  | ----                          |
| Cash flows from investing activities                      |  |   |                               |
| Capital expenditures .....                                | --                                     | --  | (13)                          |
|   | ----                                   | ----  | ----                          |
| Cash used in investing activities .....                   | --                                     | --  | (13)                          |
|   | ----                                   | ----  | ----                          |
| Cash flows from financing activities                      |  |   |                               |
| Dividends to shareholders .....                           | --                                     | (9)   | --                            |
| Proceeds from long-term debt .....                        | 95                                     | --  | 2                             |
| Repayment of long-term debt .....                         | (85)                                   | --  | (2)                           |
| Intercompany .....  | (31)                                   | 11  | 20                            |
| Increase in notes payable .....                           | --                                     | --  | 1                             |
|   | ----                                   | ----  | ----                          |



## Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

|   |      |      |       |
|---|------|------|-------|
| Cash (used in) provided by financing activities ..... | (21) | 2    | 21    |
|   | ---- | ---  | ----  |
| Effect of exchange rate changes on cash .....         | --   | --   | 1     |
|   | ---- | ---  | ----  |
| Decrease in cash and cash equivalents .....           | (3)  | --   | (40)  |
| Cash and cash equivalents at beginning of year .....  | 5    | --   | 109   |
|   | ---- | ---  | ----  |
| Cash and cash equivalents at end of period .....      | \$ 2 | \$-- | \$ 69 |
|   | ==== | ===  | ====  |

26

### Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

#### Restatement of Financial Statements

The Company restated its financial statements for the years 1998 through 2002 and for the first quarter of 2003, to correct errors in its accounting for deferred taxes relating to its Equistar investment, the calculation of its pension benefit obligations and its accounting for a multi-year precious metals agreement. The Company's independent auditors, PwC, concur with the Company's decision to restate its financial statements.

Deferred tax assets and liabilities and deferred tax expense for the years 1998 through 2002 and for the first quarter of 2003 were restated to appropriately account for the Company's book and tax basis differences associated with its investment in Equistar in accordance with SFAS No. 109. The accounting for deferred taxes associated with Equistar was previously based on the difference between book and tax basis of a subsidiary that holds the partnership investment. Deferred tax is now based on the difference between book and tax basis of the actual partnership interest held by the subsidiary. The effect of the adjustments to deferred tax assets and liabilities was to increase net deferred tax liabilities by \$425 million, increase Accumulated deficit by \$440 million and decrease Cumulative other comprehensive loss by \$15 million at December 31, 2002. The effect of the adjustments to Benefit from income taxes for the three months ended March 31, 2003 was an increase of \$24 million, and for the three months ended March 31, 2002 was less than \$1 million. In addition, during the course of its review of its deferred taxes, the Company concluded that its realization of a deferred tax asset of \$10 million related to its French subsidiaries was unlikely. The elimination of this deferred tax asset as of December 31, 2002 resulted in an increase of \$10 million in net deferred tax liabilities and Accumulated deficit.

The Company's accrued pension benefit costs, included in Other liabilities, and its net periodic pension benefit cost were restated for 2002 and for the first quarter of 2003. The restatement corrected errors in the calculation of the Company's pension liability. The Company's principal actuarial firm incorrectly utilized participant data in its 2002 actuarial valuation and underestimated the accumulated pension benefit obligation at December 31, 2002 for the Company's largest domestic pension plan. The effect of these corrections was to increase accrued pension benefit cost by \$53 million, decrease net deferred tax liabilities by \$19 million, increase Accumulated deficit by \$1

Edgar Filing: MILLENNIUM CHEMICALS INC - Form 10-Q/A

million and increase Cumulative other comprehensive loss by \$33 million at December 31, 2002. The changes to net periodic pension benefit cost due to this restatement for the three months ended March 31, 2003 and 2002 were each less than \$1 million.

The Company also restated its financial statements for the years 1998 through 2002 and for the first quarter of 2003 due to a change in accounting treatment for a five-year agreement entered into in 1998 that provides the Company with the right to use gold owned by a third party, as more fully described in Note 7 to the Consolidated Financial Statements included in this Quarterly Report. The Company previously accounted for this agreement as an operating lease but is now accounting for this agreement as a secured financing. As a result, Other assets were increased by \$4 million, Current liabilities were increased by \$13 million, net deferred tax liabilities were decreased by \$4 million, and Accumulated deficit was increased by \$5 million at December 31, 2002. This restatement changed Operating income by less than \$1 million for the three months ended March 31, 2003 and decreased Operating income for the three months ended March 31, 2002 by \$1 million.

In addition, \$2 million of S,D&A costs allocated to the Company's investment in Equistar and previously reported in Loss on Equistar investment for each of the three months ended March 31, 2003 and 2002 have been reclassified to Selling, development and administrative expense in the Company's Consolidated Statements of Operations.

The Company has filed an amendment to its Annual Report on Form 10-K for the year ended December 31, 2002 to reflect the above-described corrections.

Introduction

The Company's principal operations are grouped into three business segments: Titanium Dioxide and Related Products, Acetyls, and Specialty Chemicals. Operating income and expense not identified with the three separate business segments, including certain of the Company's S,D&A costs not allocated to its three business segments, employee-related costs from predecessor businesses and certain other expenses, are reflected as Other. The Company also holds a 29.5% interest in Equistar, which is accounted for using the equity method (see Note 1 to the Consolidated Financial Statements included in this Quarterly Report.) A discussion of Equistar's financial results for the reltyle=' margin-bottom:0

CHARLES B. JOHNSON hereby appoints BARBARA J. GREEN his true and lawful attorney-in-fact and agent to execute and file with the Securities and Exchange Commission any Schedule 13G or 13D, any amendments thereto or any related documentation which may be required to be filed in his individual capacity as a result of his position as an officer, director or shareholder of Franklin Resources, Inc. and, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing which he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, may lawfully do or cause to be done by virtue hereof.

Date: 9-11-03

/s/Charles B. Johnson

-----  
Charles B. Johnson

POWER OF ATTORNEY

RUPERT H. JOHNSON hereby appoints BARBARA J. GREEN his true and lawful attorney-in-fact and agent to execute and file with the Securities and Exchange Commission any Schedule 13G or 13D, any amendments thereto or any related documentation which may be required to be filed in his individual capacity as a result of his position as an officer, director or shareholder of Franklin Resources, Inc. and, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing which he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, may lawfully do or cause to be done by virtue hereof.

Date: Sept 4, 2003

/s/Rupert H. Johnson, Jr.

-----  
Rupert H. Johnson



Exhibit C

|   |                             |
|---|-----------------------------|
| Franklin Advisers, Inc.                     | Item 3 classification: 3(e) |
| Templeton Asset Management Ltd.             | Item 3 Classification: 3(e) |
| Franklin Templeton Portfolio Advisors, Inc. | Item 3 classification: 3(e) |
| Fiduciary Trust Company International       | Item 3 classification: 3(b) |



